573758-69-7

Basic information

• Product Name: 1-Isoquinolinecarbonitrile,4-amino-(9CI)
• Synonyms: 1-Isoquinolinecarbonitrile,4-amino-(9CI);4-AMinoisoquinoline-1-carbonitrile
• CAS NO: 573758-69-7
• Molecular Formula: C10H7N3
• Molecular Weight: 169.186
• Product Categories: ISOQUINOLINE
• Mol File: 573758-69-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 464.465°C at 760 mmHg
• Flash Point: 234.7°C
• Appearance: /
• Density: 1.295g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.696
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-Isoquinolinecarbonitrile,4-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Isoquinolinecarbonitrile,4-amino-(9CI)(573758-69-7)
• EPA Substance Registry System: 1-Isoquinolinecarbonitrile,4-amino-(9CI)(573758-69-7)

Safety Data

• Hazardous Substances Data: 573758-69-7(Hazardous Substances Data)

Usage

Type of chemical

Derivative of isoquinoline

Contains

An amino group and a cyano group

Usage

Synthesis of pharmaceuticals, agrochemicals, dyes, and pigments

Potential

Building block for the creation of other organic compounds, used in various chemical reactions and processes

Biological activity

Potential biological activity

Applications

Used in the production of dyes and pigments.

InChI:InChI=1/C10H7N3/c11-5-10-8-4-2-1-3-7(8)9(12)6-13-10/h1-4,6H,12H2

Upstream product

• 1013-88-3 Benzophenone imine 
• 27224-09-5 4-Bromo-isoquinoline-1-carbonitrile 
• 76144-87-1 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl 
• 573758-64-2 4-(2,4-Dimethoxy-benzylamino)-isoquinoline-1-carbonitrile 

Relevant articles and documents

METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Bicyclic modulators of androgen receptor function

The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula I wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.